Ciprofloxacin (Cipro 250 mg) and Ubrogepant: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
CYP3A4 inhibition can increase ubrogepant exposure and requires label-specific dose modification.
Clinical significance and safety
Ciprofloxacin may increase ubrogepant exposure. The ubrogepant label calls for a modified regimen with interacting CYP3A4 inhibitors, and some combinations also restrict repeat dosing. A prescriber or pharmacist should check the exact dose and timing before use.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.